Reach Us +44-3308187254


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
New Methods For Optimizing Drug Dosage Regimens For Maximally Precise Individualized Therapy | 13289
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

New methods for optimizing drug dosage regimens for maximally precise individualized therapy

International Summit on Clinical Pharmacy & Dispensing

Roger W. Jelliffe

ScientificTracks Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.002

Optimal dosage individualization methods include: 1) Nonparametric (NP), not parametric (P) population models. P models estimate parameter means and variances. Dosage uses only central tendencies. NP models estimate entire distributions, using multiple discrete support points. Each point has a model parameter estimate, plus the probability of each point in the population. Those support points permit 2) Multiple Model (MM) dosage design. A candidate regimen predicts multiple future serum concentrations. One computes the weighted squared error of its failure to hit the target, and then finds the maximally precise regimen having minimum error. Depending on each patient, four Bayesian methods are used. 1) MM analysis is used routinely. Support points having parameter values fitting his/her serum data well become more probable - those that do not - less so. The Bayesian posterior joint density is thus found. MM dosage design is again used. 2) For unusual patients outside the ranges of the NP model, a Hybrid method first uses a maximum aposteriori probability (MAP) procedure locating the general area, often beyond the model ranges. Extra support points (up to 10x10) augment the original NP population for subsequent MM analysis. 3) For highly unstable patients having changing parameter values, the interacting multiple model (IMM) tracks drug behavior best. Using these methods in relevant clinical situations will be demonstrated.
Roger W. Jelliffe MD, FCP, FAAPS, developed the first computer software for individualizing drug dosage regimens in 1967. He was the first to relate renal drug elimination to creatinine clearance. He developed the first method for estimating creatinine clearance when serum creatinine is changing. He founded the USC Laboratory of Applied Pharmacokinetics in 1973, and the USC*PACK and more recent MM-USCPACK clinical software for individualizing drug dosage regimens most precisely.His laboratory developed the Resource for Population Modeling at the San Diego Supercomputer Center, the nonparametric adaptive grid (NPAG) population modeling approach, and Multiple Model (MM) design of maximally precise dosage regimens. This is now the Bestdose clinical and Pmetrics research software. We have developed three new methods of Bayesian analysis for individual patients. This adds great capability and safety in managing unusual patients.Dr. Jelliffe?s interest is now in nonlinear PK/PD population modeling of multiple interacting drug systems, optimally coordinated combination MM dosage regimens for patients, and in methods using the dose itself as an active partner to learn about the patient optimally while having to treat him/her at the same time. He is author or co-author of 132 peer reviewed publications, has mentored over 100 visiting scientific scholars, 1 sabbatical scholar, 2 Master?s Students, 3 Ph.D. candidates, and 3 mini-sabbaticals.